The in vitro incubation of phytohemagglutinin-stimulated peripheral blood lymphocytes with thymosin results in a marked and reproducible increase in production of T-cell growth factor, which is dose dependent and most pronounced in the first 24 hr of culture. Incubation of lymphocytes with thymosin alone failed to induce any production of Tcell growth factor. The biological activity of thymosin fraction 5 cannot be attributed to the activity of thymosin a,, one of the well-characterized peptide components of fraction 5. These data provide the basis for (i) a potential mechanism for the in vivo immunorestorative effects of thymosin in primary and secondary immunodeficiencies and (ii) identification of an additional, but as yet undefined, immunoregulatory component of thymosin fraction 5.
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The lymphokines are a group of mediators elaborated by activated lymphocytes that have important effects in the cascade of events following lymphocyte stimulation. T-cell growth factor (TCGF), also referred to as interleukin 2 (IL-2), has been widely studied (1) and is known to influence Tcell maturation, production of other lymphokines such as yinterferon (y-IFN) (2) , and induction of natural killer and Tcell cytolytic activity (3, 4) . Recent attention has been focused both on the lack of TCGF production in certain immunodeficiency states and on the immunoregulatory potential of TCGF in enhancing depressed natural killer and virus specific cytotoxicity (5) .
The thymosins are a family of thymic humoral factors that have been proposed as hormonal agents with important immunoregulatory effects (6) . Thymosins, as well as other thymic preparations, are being tested extensively in vivo, as biological response modifiers in clinical trials and experimental models of primary and secondary immunodeficiencies, including acquired immunodeficiency syndrome (AIDS), autoimmune disease, neoplasia, and aging (7) (8) (9) (10) (11) (12) (13) (14) . The biological properties of two of these peptides, thymosins a1 and f34, have been studied extensively (12, 13) . It has been suggested from earlier studies that these two peptides do not account for all the biological activity of the parent compound (15) (16) (17) .
Since F5 increases immune responsiveness in children with primary immunodeficiencies (7) and in cancer patients (10) , and is being tested in clinical trials of autoimmune disease (9) and the pre-AIDS complex (8), we asked whether F5 functions, at least in part, by modulating TCGF production. It has been reported that F5 and thymosin a1 increase production of migration inhibition factor (MIF) in the mouse and guinea pig (18, 19) and production of a-and y-IFN in mice (20) and humans (21) . Thymulin (FTS, facteur thymique serique), another thymic factor, has been shown to increase TCGF production by cells of nude mice (22) . Grinblat et al. have reported increased TCGF production by thymic humoral factor (THF) in aged animals (23) .
In this paper, we report that F5 substantially and consistently augments production of TCGF by peripheral blood lymphocytes (PBL) from normal human volunteers, in a dose-dependent fashion. These data have important connotations since this system provides (i) the rationale for the augmentation and immunological responses observed in vivo in immunodeficiencies treated with thymosin; (it) the opportunity to study the mechanisms of action of thymosin in the modulation of lymphokine production; and (iii) a quantitative bioassay for isolation and characterization of one or more biologically active components of F5.
MATERIALS AND METHODS
Generation of TCGF. Human PBL were obtained from heparinized blood by separation on lymphocyte separation medium (Litton Bionetics). Cells were washed, resuspended in RPMI 1640 medium supplemented with 25 mM Hepes buffer, 1% human type AB serum, gentamycin, and L-glutamine. The PBL were cultured in 12-well plates on a platform rocker at 37°C, in 5% C02/95% air, for 24-96 hr at 1 x 106 per ml in 2 ml containing phytohemagglutinin (PHA; Burroughs Wellcome, Research Triangle Park, NC) at 2 ,ug/ml and in the presence or absence of thymosin. At the end of the culture, the supernatants were collected and stored at 4°C until assayed.
TCGF Assay. Supernatants were tested at several dilutions (1:2 to 1:32) on the TCGF-dependent C57BL/6-derived CT-6 mouse cell line, as previously described (24) . CT 
RESULTS
Enhancement of TCGF Production by Thymosin. In our initial studies, PBL from 23 normal donors were screened for PHA-induced TCGF production in the presence or absence of F5 (100 ,ug/ml) after 72 hr of culture. Forty-eight percent of the individuals tested showed a significant enhancement of TCGF production by F5 (mean fold increase = 2.6 ± 0.7). Since net TCGF detectible in supernatant at 72 hr reflects a balance between production and utilization (25), a kinetic study was performed to determine the time at which thymosin-induced enhancement of TCGF production was optimal 138.8 141.4 1.9 *Donor PBL from five different individuals were cultured for the times shown prior to collection of supernatants. PBL from donors A-C were freshly isolated from whole blood. PB3L from donors D and E were cryopreserved and thawed prior to testing. *Cells were cultured in the absence of F5 (-F5) or in the presence of F5 at 100 ,g/ml (+F5). Supernatants were tested on CT-6 cells. ( Table 1) . Although the peak of TCGF production is between 48 and 72 hr for most individuals, the optimal effect of F5 in increasing PHA-induced TCGF production was seen at the earliest timepoint studied-i.e., 24 hr of culture. Enhancement of PHA-induced TCGF by F5 also was demonstrated in PBL that had been cryopreserved and thawed prior to stimulation with PHA. No effect of F5 or thymosin a1 on TCGF production has been observed in the absence of PHA (data not shown).
Thymosin Dose and Role of Thymosin a. The dose dependence of the thymosin-enhanced production of TCGF is shown in Fig. 1. F5 causes an increase in PHA-induced TCGF production in a linear dose-dependent fashion reaching maximal stimulation at 400 ,g/ml. The increases are statistically significant (P < 0.01 or 0.001) at all concentrations of F5 .25 ,g/ml. At high concentrations, thymosin a, causes a small increase in TCGF production, which does not account for all the biological activity of F5, since thymosin a1 is approximately 0.6% of the total protein in F5. The two different lots of F5 (BP100 and C114080) yield virtually identical results. An additional 10 lots of F5 also have been tested, and all show biological activity in this assay (data not shown), although some lots of thymosin a1 have little or no activity. Neither control kidney fraction 5 nor ,13 peptide results in significant increases of TCGF production.
To assess individual variability of TCGF production in re- tData are expressed as units/ml in supernatants generated after 24 hr in the presence of PHA. tWhen PBL were cultured in the presence of PHA and F5 at either 100 or 200 Ag/ml, the percent increase in TCGF production was calculated as % increase = 100 x [units/ml (+F5) -urfits/ml (-F5)]/units/ml (-F5) . A -indicates not tested. The mean increase (±SEM) for each dose of P5 is shown as x at the bottom of each column. These increases were significant at P < 0.01.
donors were retested multiple times. The data shown in Ta (19) of the effects of thymectomy. In contrast, our data suggest an immunoregulatory effect of F5 upon PHA-induced TCGF production by mature PBL, rather than an influence upon pre-T-cell differentiation and maturation. The biological activity responsible for the induction of both migration inhibition factor and y-IFN has been attributed to thymosin a,, and the biological activity in F5 could be accounted for by its a1 content (19, 20) . On the other hand, the present studies indicate that a new component of thymosin F5 other than, or in addition to, a, is responsible for the increased production of TCGF by PBL. Several earlier studies have in fact shown that a component of F5 other than thymosin a, or f4 is responsible for phenotypic changes in immature murine thymocytes (16) , induction of cGMP in murine thymocytes (17) , and increased mixed lymphocyte response and cytotoxic T-cell response by murine thymocytes (6, 15) . These latter observations are particularly relevant, since these increased responses could have been mediated by increased TCGF production.
There are several possible explanations for the observed data: (i) thymosin may be acting via the macrophage by inducing increased interleukin 1 production or directly inducing a helper T cell to augment or accelerate TCGF production; (it) thymosin could be acting to inhibit utilization of TCGF by modulation of the appearance of TCGF receptors (25) ; and (iii) thymosin may be acting by a combination of these mechanisms. The early appearance of increased TCGF favors the first interpretation.
On the basis of the data presented in this report, it may be possible not only to define additional functionally active components of F5 but also to identify a major activity of thymosin in the maintenance and regulation of T-cell function. Since lymphokine production may be a key step in the immunological events leading to y-IFN production and generation of effector cells (1) (2) (3) (4) , and since lymphokine production is reported to be deficient in several clinical states, including aging (26), autoimmune disease, (27) and AIDS (5, 8) , modulation of TCGF production by thymosin provides a rational basis for therapeutic intervention. These results also provide an experimental basis for the immunoenhancing effects of thymosin in vitro.
